Clinical Trial Update: Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 study evaluating trastuzumab, ixabepilone, and carboplatin in HER2-positive metastatic breast cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• HERCEPTIN (trastuzumab)
• Ixempra (ixabepilone)
• Paraplatin (Carboplatin)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: HER2-positive Breast Cancer, Male Breast Cancer | Phase 2 | Status: COMPLETED | Results posted: 2011-04-04